Signal
Celcuity’s gedatolisib shows positive phase 3 results in breast cancer, advancing FDA filings
Evidence first: scan the strongest sources, then decide whether to go deeper.
Published 2026-05-04 12:08 UTCUpdated 2026-05-04 16:23 UTC
redditrss
clinical_trialsfdadrug_developmentbiotech_fundingr_and_dsafety_signals
Source links open
Source links and full evidence are open here. Archive history, compare-over-time, alerts, exports, API, integrations, and workflow are paid.
No card needed for the free brief.
Evidence trail (top sources)
top sources (2 domains)domains are deduped. counts indicate coverage, not truth.2 top sources shown
limited source diversity in top sources
Overview
Celcuity’s pan-PI3K/mTOR inhibitor gedatolisib has met the primary endpoint in the phase 3 Viktoria-1 trial for HR+ metastatic breast cancer, demonstrating significantly longer progression-free survival compared to Novartis’ Piqray in PIK3CA-mutant patients.
Score total
1.52
Momentum 24h
3
Posts
3
Origins
3
Source types
2
Duplicate ratio
0%
Why now
- FDA decision on the initial application is expected by July 17, 2026, making recent data timely for regulatory filings.
- Upcoming ASCO 2026 meeting offers a platform to showcase new clinical data to the oncology community.
- Competition with established PI3K inhibitors highlights the importance of demonstrating clinical benefit in phase 3 trials.
Why it matters
- Positive phase 3 results increase the likelihood of FDA approval for a new breast cancer therapy.
- Demonstrated superiority over an established PI3K inhibitor (Piqray) could shift clinical practice for HR+ metastatic breast cancer.
- Broader approval could expand treatment options for patients with both PIK3CA-mutant and wild-type tumors.
LLM analysis
Topic mix: lowPromo risk: lowSource quality: medium
Recurring claims
- Celcuity’s gedatolisib met the primary endpoint in the phase 3 Viktoria-1 trial, showing longer progression-free survival than Novartis’ Piqray in PIK3CA-mutant HR+ metastatic breast cancer patients.
- The positive phase 3 results support a second FDA submission for gedatolisib, which is already under review for PIK3CA-wild-type breast cancer, with a decision expected by July 17, 2026.
How sources frame it
- Biotech Community And Media: supportive
All evidence
All evidence
Celcuity strengthens case for ASCO-spotlighted breast cancer drug
BioPharma Dive · biopharmadive.com · 2026-05-04 16:23 UTC
Cellcuity PIK3CA/mTOR Inhibitor Hits in HR+ mBC in PIK3A WT and mutant Populations
biotech · reddit.com · 2026-05-04 13:15 UTC
A phase 3 trial of Celcuity’s pan-PI3K/mTOR inhibitor has hit its primary endpoint, clearing the biotech to file a second submission for a molecule already under review by the FDA.
Fierce Biotech · fiercebiotech.com · 2026-05-04 12:08 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 3Origin domains: 3Duplicates: -
Showing 3 / 0
Top publishers (this list)
- BioPharma Dive (1)
- biotech (1)
- Fierce Biotech (1)
Top origin domains (this list)
- biopharmadive.com (1)
- reddit.com (1)
- fiercebiotech.com (1)